Related Experiment Videos
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in
A Dart1, G Jerums, G Nicholson
1Alfred Hospital, Prahran, Victoria, Australia.
Insights
Atorvastatin demonstrated superior efficacy over simvastatin in lowering LDL cholesterol and other lipids in hypercholesterolemic patients. Both statins showed comparable safety profiles with no serious adverse events.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Research
Background:
- Hypercholesterolemia is a significant risk factor for cardiovascular disease.
- Statins are widely prescribed to manage high cholesterol levels.
- Direct comparisons of atorvastatin and simvastatin efficacy and safety are crucial for clinical decision-making.
Purpose of the Study:
- To directly compare the safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
- To evaluate lipid profile changes and achievement of LDL cholesterol targets.
- To assess the incidence of adverse events associated with both statins.
Main Methods:
- A 1-year, randomized, double-blind study involving 177 hypercholesterolemic patients.
- Patients received once-daily atorvastatin 10 mg or simvastatin 10 mg, with dose titration to 20 mg at week 16 if LDL cholesterol targets were not met.
- Efficacy measured by percent change in various lipids; safety assessed by monitoring liver enzymes and creatine phosphokinase.
Main Results:
- Atorvastatin significantly reduced LDL cholesterol, total cholesterol, VLDL cholesterol, triglycerides, and apolipoprotein B compared to simvastatin (p <0.05).
- At week 16, 46% of patients on atorvastatin 10 mg achieved LDL cholesterol target, versus 27% on simvastatin 10 mg.
- No clinically significant elevations in liver enzymes or creatine phosphokinase were observed in either group; no serious adverse events were treatment-related.
Conclusions:
- Atorvastatin exhibits greater efficacy in lowering LDL cholesterol and other lipid parameters than simvastatin at equivalent doses.
- Both atorvastatin and simvastatin demonstrate favorable safety profiles in hypercholesterolemic patients.
- The superior lipid-lowering profile of atorvastatin suggests broader clinical utility for achieving cholesterol targets.
Abstract:
We directly compared the safety and efficacy of atorvastatin and simvastatin in hypercholesterolemic patients. This 1-year, randomized, double-blind study was performed at 9 community- and university-based research hospitals in Australia. One-hundred seventy-seven patients between the ages of 18 and 80 years with baseline low-density-lipoprotein (LDL) cholesterol > or = 4.14 and < or = 7.76 mmol/L (160 and 300 mg/dl, respectively) and triglycerides < or = 4.52 mmol/L (400 mg/dl) received once-daily dosing with atorvastatin (Lipitor) 10 mg or simvastatin (Zocor) 10 mg. At week 16, the dose of medication was titrated to atorvastatin 20 mg or simvastatin 20 mg if patients did not meet LDL cholesterol target of < or = 3.36 mmol/L (130 mg/dl). Efficacy was reported as percent change from baseline in LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, total triglycerides, high-density lipoprotein cholesterol, apolipoproteins AI and B, and lipoprotein(a). Atorvastatin caused significantly greater reductions from baseline than did simvastatin for LDL cholesterol, total cholesterol, very low density lipoprotein cholesterol, triglycerides, and apolipoprotein B (p <0.05). No patient in either treatment group had clinically important elevations in creatine phosphokinase, alanine aminotransaminase, or aspartate aminotransaminase. No serious adverse events were considered associated with treatment. With atorvastatin 10 mg, 46% of the patients achieved LDL cholesterol target goal by week 16, whereas only 27% of the simvastatin patients achieved the target goal at the 10-mg dose. This cholesterol-lowering profile affords utility in many patient types.